Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(57.1%)
Phase 1
2(28.6%)
Phase 2
1(14.3%)
7Total
N/A(4)
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04965987Phase 1Withdrawn

Oxaloacetate in Myasthenia Gravis

Role: collaborator

NCT05273372Not ApplicableCompleted

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

Role: lead

NCT05840237Not ApplicableCompleted

REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID

Role: lead

NCT04204889Phase 1Completed

Trial of Oxaloacetate in ALS

Role: collaborator

NCT04592354Not ApplicableUnknown

Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors

Role: lead

NCT03509714Not ApplicableCompleted

Oxaloacetate Supplementation for Emotional PMS

Role: lead

NCT01741701Phase 2Completed

A Pilot Study of Oxaloacetate in Subjects With Treated PD

Role: collaborator

All 7 trials loaded